查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2028424

感染疾病照護現場診斷市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Infectious Disease Point-of-care Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 請詢問到貨日

價格

感染疾病照護現場（POC）市場成長要素

由於醫療保健重點的轉變和診斷技術的進步，全球感染疾病照護現場診斷市場正經歷顯著的變革時期。該市場在2025年的價值為143.7億美元，預計到2026年將萎縮至139.7億美元，到2034年將達到111.3億美元，預測期內的複合年成長率為-2.80%。儘管市場萎縮，北美仍維持領先地位，在2025年佔36.30%的市佔率。這得歸功於其強大的醫療保健基礎設施和持續的產品創新。

照護現場診斷技術能夠在患者身邊快速檢測疾病，無需前往集中式檢查室進行檢測。這些檢測可在15-30分鐘內提供結果，進而改善治療決策和患者預後。多重就地檢驗（MPOCT）、微流體和奈米技術等技術進步提高了檢測的準確性、速度和易用性，使其成為現代醫療保健系統不可或缺的解決方案。

市場動態

成長要素

愛滋病、肝炎、流感和結核病等感染疾病的全球蔓延仍然是推動即時診斷（POC）發展的主要動力。全球健康數據顯示，每年有數百萬人受到影響，這使得快速且方便的診斷解決方案的需求持續存在。

另一個重要的促進因素是醫療衛生系統向分散式管理的轉變。就地檢驗使得在診所、家中和偏遠地區進行診斷成為可能，從而減少了對集中式檢測機構的依賴。這一趨勢在新冠疫情期間加速發展，並持續影響醫療衛生服務模式。

此外，診斷平台的技術進步，包括分子診斷和基於奈米技術的檢測，提高了靈敏度並縮短了結果的時間。這些創新正在擴大即時診斷（POC）在多種疾病中的應用範圍。

市場限制因素

儘管有這些促進因素，但由於新冠疫情後緊急偵測需求下降，市場規模正在萎縮。此外，人們對檢測準確性的擔憂以及發展中地區熟練專業人員的短缺也限制了其普及。操作不當導致的錯誤以及培訓不足引發的問題仍然是市場成長面臨的挑戰。

市場趨勢

塑造市場格局的關鍵趨勢之一是將奈米技術應用於診斷設備。利用奈米顆粒的檢測方法能夠實現高靈敏度和快速檢測，通常只需極少量的檢體。這些創新正在吸引大量研發投資，並持續提升診斷能力。

另一個趨勢是開發能夠一次檢測多種病原體的多重診斷平台。這將提高效率並縮短檢測時間，尤其是在重症監護環境中。

此外，隨著以患者為中心的醫療保健和診斷方式的轉變，以便利性為優先，家用和自測檢測套組的使用率也不斷提高。

細分分析

依技術分類，市場包括側向流動免疫檢測、分子診斷、凝集試驗和流通檢測。側向流動免疫檢測因其操作簡便、結果快速且應用廣泛而佔市場主導地位，預計到2026年將佔31.2%的市場佔有率。

依疾病分類，市場涵蓋愛滋病、流感、結核病、肝炎、抗甲氧西林金黃色葡萄球菌（MRSA）感染等。其中，困難梭狀芽孢桿菌傳染病（CDI）由於其高發病率和醫院檢測需求不斷成長，佔了較大的市場佔有率。

從終端用戶角度來看，市場細分為醫院床邊檢測、診所、急診診所、居家檢測和養老院。受住院患者數量不斷增加以及對即時診斷結果需求的推動，醫院床邊檢測佔主導地位。同時，居家檢測和急診診所因其便利性和可近性而備受關注。

區域趨勢

核准先進的醫療保健體系、強力的法規核准以及主要企業之間的戰略合作，北美預計將保持其領先的市場地位，2025 年市場規模將達到 52.2 億美元，2026 年將達到 50.7 億美元。

歐洲市佔率位居第二，這主要得益於大型企業的併購和產品系列的擴張。亞太地區預計將展現出最高的成長潛力，這得益於中國和印度等國家醫療保健投資的增加、疾病負擔的加重以及診斷技術普及程度的提高。

由於意識水平低和醫療費用支出低，拉丁美洲、中東和非洲的成長速度緩慢，但基礎設施的逐步發展有望支撐未來的需求。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家主要感染疾病流行率
  • 新產品發布
  • 主要產業趨勢（合併、收購、合作等）
  • 感染疾病照護現場診斷的技術進步
  • 新冠疫情對感染疾病照護現場診斷市場的影響
  • 新興國家感染疾病照護現場診斷相關措施概述
  • 主要企業針對各種感染疾病的照護現場診斷價格分析
  • 某主要企業對主要感染疾病照護現場診斷的功能分析

第5章：2021-2034年全球感染疾病照護現場診斷市場分析、洞察與預測

  • 市場分析、洞察與預測：按方法論分類
    • 側向流動免疫檢測（LFIA）
    • 凝集反應試驗
    • 流通式檢測/免疫濃縮試驗
    • 分子診斷
    • 其他
  • 市場分析、洞察與預測：按疾病分類。
    • 人類免疫力缺乏病毒（HIV）
    • 乙型肝炎病毒（HBV）
    • 肺炎/鏈球菌感染疾病
    • 呼吸道融合細胞病毒（RSV）
    • 流感
    • 困難梭狀芽孢桿菌傳染病（CDI）
    • C型肝炎病毒（HCV）
    • 抗藥性金黃色葡萄球菌（MRSA）
    • 結核病（TB）
    • COVID-19
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院床邊
    • 診所
    • 急診診所和零售診所
    • 家庭檢測和自我檢測
    • 護理機構
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美感染疾病照護現場診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲感染疾病照護現場診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區感染疾病照護現場診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太地區

第9章：拉丁美洲感染疾病照護現場診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第10章：中東和非洲感染疾病照護現場診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Quest Diagnostics Incorporated
    • BD
    • bioMerieux SA
    • Cardinal Health, Inc.
    • Cepheid
    • Mesa BIoTech
    • Trinity BIoTech
    • Quidel Corporation
    • Bio-Rad Laboratories, Inc.
    • Abbott
    • 其他主要企業
Product Code: FBI104307

Growth Factors of infectious disease point-of-care (POC) diagnostics Market

The global infectious disease point-of-care (POC) diagnostics market is undergoing a notable transition due to shifting healthcare priorities and evolving diagnostic technologies. The market was valued at USD 14.37 billion in 2025 and is projected to decline to USD 13.97 billion in 2026, further reaching USD 11.13 billion by 2034, reflecting a CAGR of -2.80% during the forecast period. Despite the decline, North America dominated the market with a 36.30% share in 2025, driven by strong healthcare infrastructure and continuous product innovations.

Point-of-care diagnostics enable rapid disease detection near the patient, eliminating the need for centralized laboratory testing. These tests provide results within 15-30 minutes, improving treatment decisions and patient outcomes. Technological advancements such as multiplex point-of-care testing (MPOCT), microfluidics, and nanotechnology have enhanced accuracy, speed, and usability, making these solutions vital in modern healthcare systems.

Market Dynamics

Growth Drivers

The increasing global prevalence of infectious diseases such as HIV, hepatitis, influenza, and tuberculosis remains a major driver for POC diagnostics. According to global health data, millions of people are affected annually, creating sustained demand for rapid and accessible diagnostic solutions.

Another important driver is the shift toward decentralized healthcare systems. Point-of-care testing allows diagnosis in clinics, homes, and remote settings, reducing dependency on centralized laboratories. This trend gained momentum during the COVID-19 pandemic and continues to influence healthcare delivery models.

Additionally, technological advancements in diagnostic platforms, including molecular diagnostics and nanotechnology-based testing, are improving sensitivity and reducing turnaround time. These innovations are expanding the application scope of POC diagnostics across multiple diseases.

Market Restraints

Despite these drivers, the market is experiencing a decline due to reduced demand post-COVID-19 pandemic, as emergency testing requirements have subsided. Furthermore, accuracy concerns and lack of skilled professionals in developing regions limit adoption. Errors caused by improper handling and insufficient training continue to challenge market growth.

Market Trends

A key trend shaping the market is the integration of nanotechnology in diagnostic devices. Nanoparticle-based tests offer high sensitivity and rapid detection, often requiring minimal sample volumes. These innovations are attracting significant research investments and improving diagnostic capabilities.

Another trend is the development of multiplex diagnostic platforms, which allow simultaneous detection of multiple pathogens in a single test. This enhances efficiency and reduces testing time, especially in critical care settings.

The market is also witnessing increased adoption of home-based and self-testing kits, reflecting a shift toward patient-centric healthcare and convenience-driven diagnostics.

Segmentation Analysis

By technique, the market includes lateral flow immunoassay, molecular diagnostics, agglutination tests, and flow-through assays. The lateral flow immunoassay segment dominates due to its simplicity, rapid results, and widespread availability. It is expected to hold a 31.2% share in 2026.

By disease, the market covers HIV, influenza, tuberculosis, hepatitis, MRSA, and others. Among these, clostridium difficile infections (CDI) hold a significant share due to high prevalence and increased testing demand in hospitals.

By end-user, the market is segmented into hospital bedside, physician offices, urgent care clinics, home testing, and nursing homes. The hospital bedside segment leads, driven by the growing number of hospitalized patients and the need for immediate diagnostic results. Meanwhile, home testing and urgent care clinics are gaining traction due to convenience and accessibility.

Regional Insights

North America leads the market with a value of USD 5.22 billion in 2025 and USD 5.07 billion in 2026, supported by advanced healthcare systems, strong regulatory approvals, and strategic collaborations among key players.

Europe holds the second-largest share, driven by mergers, acquisitions, and product portfolio expansion by major companies. Asia Pacific is expected to witness the highest growth potential, supported by increasing healthcare investments, rising disease burden, and expanding access to diagnostic technologies in countries such as China and India.

Latin America and the Middle East & Africa show slower growth due to limited awareness and lower healthcare spending, though gradual improvements in infrastructure are expected to support future demand.

Competitive Landscape

The market is semi-consolidated, with leading players such as F. Hoffmann-La Roche Ltd, Abbott Laboratories, Cepheid Inc., Thermo Fisher Scientific, and BD. These companies focus on product innovation, strategic partnerships, and acquisitions to strengthen their market presence.

Recent developments include the launch of rapid diagnostic kits, multiplex assays, and portable testing devices, highlighting continuous innovation in the sector.

Conclusion

The infectious disease point-of-care diagnostics market is projected to decline from USD 14.37 billion in 2025 to USD 11.13 billion by 2034, primarily due to reduced post-pandemic demand and operational challenges. However, ongoing advancements in diagnostic technologies, increasing disease prevalence, and the shift toward decentralized healthcare will continue to support long-term relevance and innovation in the market.

Segmentation By Technique

  • Lateral Flow Immunoassay (LFIA)
  • Agglutination Test
  • Flow-through test/Immunoconcentration Assay
  • Molecular Diagnostics
  • Others

By Disease

  • HIV
  • Hepatitis B Virus
  • Pneumonia/Streptococcus Associated Infections
  • Respiratory Syncytial Virus (RSV)
  • Influenza
  • Clostridium Difficile Infections (CDI)
  • Hepatitis C Virus
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • Tuberculosis (TB)
  • COVID-19
  • Others

By End-User

  • Hospital Bedside
  • Physician's Office Lab
  • Urgent Care & Retail Clinics
  • Home & Self-testing
  • Nursing Home
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Infectious Diseases, By Key Countries, 2025
  • 4.2. New Product Launches
  • 4.3. Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.4. Technological Advancements in Infectious Disease Point of Care (POC) Diagnostics
  • 4.5. Impact of COVID-19 on Infectious Disease Point of Care (POC) Diagnostics Market
  • 4.6. Overview of Initiatives for Infectious Disease Point of Care (POC) Diagnostics in Emerging Countries
  • 4.7. Pricing Analysis of Various Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
  • 4.8. Analysis of Product Features of Key Infectious Disease Point of Care (POC) Diagnostics, By Key Companies

5. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technique
    • 5.1.1. Lateral Flow Immunoassay (LFIA)
    • 5.1.2. Agglutination Tests
    • 5.1.3. Flow-through Tests / Immunoconcentration Assays
    • 5.1.4. Molecular Diagnostics
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease
    • 5.2.1. Human Immunodeficiency Virus (HIV)
    • 5.2.2. Hepatitis B Virus (HBV)
    • 5.2.3. Pneumonia / Streptococcus Associated Infections
    • 5.2.4. Respiratory Syncytial Virus (RSV)
    • 5.2.5. Influenza
    • 5.2.6. Clostridium difficile infection (CDI)
    • 5.2.7. Hepatitis C Virus (HCV)
    • 5.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • 5.2.9. Tuberculosis (TB)
    • 5.2.10. COVID-19
    • 5.2.11. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospital Bedside
    • 5.3.2. Physician's Office Lab
    • 5.3.3. Urgent Care & Retail Clinics
    • 5.3.4. Home & Self-Testing
    • 5.3.5. Nursing Homes
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By Geography
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technique
    • 6.1.1. Lateral Flow Immunoassay (LFIA)
    • 6.1.2. Agglutination Tests
    • 6.1.3. Flow-through Tests / Immunoconcentration Assays
    • 6.1.4. Molecular Diagnostics
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease
    • 6.2.1. Human Immunodeficiency Virus (HIV)
    • 6.2.2. Hepatitis B Virus (HBV)
    • 6.2.3. Pneumonia / Streptococcus Associated Infections
    • 6.2.4. Respiratory Syncytial Virus (RSV)
    • 6.2.5. Influenza
    • 6.2.6. Clostridium difficile infection (CDI)
    • 6.2.7. Hepatitis C Virus (HCV)
    • 6.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • 6.2.9. Tuberculosis (TB)
    • 6.2.10. COVID-19
    • 6.2.11. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospital Bedside
    • 6.3.2. Physician's Office Lab
    • 6.3.3. Urgent Care & Retail Clinics
    • 6.3.4. Home & Self-Testing
    • 6.3.5. Nursing Homes
    • 6.3.6. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technique
    • 7.1.1. Lateral Flow Immunoassay (LFIA)
    • 7.1.2. Agglutination Tests
    • 7.1.3. Flow-through Tests / Immunoconcentration Assays
    • 7.1.4. Molecular Diagnostics
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease
    • 7.2.1. Human Immunodeficiency Virus (HIV)
    • 7.2.2. Hepatitis B Virus (HBV)
    • 7.2.3. Pneumonia / Streptococcus Associated Infections
    • 7.2.4. Respiratory Syncytial Virus (RSV)
    • 7.2.5. Influenza
    • 7.2.6. Clostridium difficile infection (CDI)
    • 7.2.7. Hepatitis C Virus (HCV)
    • 7.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • 7.2.9. Tuberculosis (TB)
    • 7.2.10. COVID-19
    • 7.2.11. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospital Bedside
    • 7.3.2. Physician's Office Lab
    • 7.3.3. Urgent Care & Retail Clinics
    • 7.3.4. Home & Self-Testing
    • 7.3.5. Nursing Homes
    • 7.3.6. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technique
    • 8.1.1. Lateral Flow Immunoassay (LFIA)
    • 8.1.2. Agglutination Tests
    • 8.1.3. Flow-through Tests / Immunoconcentration Assays
    • 8.1.4. Molecular Diagnostics
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease
    • 8.2.1. Human Immunodeficiency Virus (HIV)
    • 8.2.2. Hepatitis B Virus (HBV)
    • 8.2.3. Pneumonia / Streptococcus Associated Infections
    • 8.2.4. Respiratory Syncytial Virus (RSV)
    • 8.2.5. Influenza
    • 8.2.6. Clostridium difficile infection (CDI)
    • 8.2.7. Hepatitis C Virus (HCV)
    • 8.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • 8.2.9. Tuberculosis (TB)
    • 8.2.10. COVID-19
    • 8.2.11. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospital Bedside
    • 8.3.2. Physician's Office Lab
    • 8.3.3. Urgent Care & Retail Clinics
    • 8.3.4. Home & Self-Testing
    • 8.3.5. Nursing Homes
    • 8.3.6. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technique
    • 9.1.1. Lateral Flow Immunoassay (LFIA)
    • 9.1.2. Agglutination Tests
    • 9.1.3. Flow-through Tests / Immunoconcentration Assays
    • 9.1.4. Molecular Diagnostics
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease
    • 9.2.1. Human Immunodeficiency Virus (HIV)
    • 9.2.2. Hepatitis B Virus (HBV)
    • 9.2.3. Pneumonia / Streptococcus Associated Infections
    • 9.2.4. Respiratory Syncytial Virus (RSV)
    • 9.2.5. Influenza
    • 9.2.6. Clostridium difficile infection (CDI)
    • 9.2.7. Hepatitis C Virus (HCV)
    • 9.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • 9.2.9. Tuberculosis (TB)
    • 9.2.10. COVID-19
    • 9.2.11. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospital Bedside
    • 9.3.2. Physician's Office Lab
    • 9.3.3. Urgent Care & Retail Clinics
    • 9.3.4. Home & Self-Testing
    • 9.3.5. Nursing Homes
    • 9.3.6. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technique
    • 10.1.1. Lateral Flow Immunoassay (LFIA)
    • 10.1.2. Agglutination Tests
    • 10.1.3. Flow-through Tests / Immunoconcentration Assays
    • 10.1.4. Molecular Diagnostics
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease
    • 10.2.1. Human Immunodeficiency Virus (HIV)
    • 10.2.2. Hepatitis B Virus (HBV)
    • 10.2.3. Pneumonia / Streptococcus Associated Infections
    • 10.2.4. Respiratory Syncytial Virus (RSV)
    • 10.2.5. Influenza
    • 10.2.6. Clostridium difficile infection (CDI)
    • 10.2.7. Hepatitis C Virus (HCV)
    • 10.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • 10.2.9. Tuberculosis (TB)
    • 10.2.10. COVID-19
    • 10.2.11. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospital Bedside
    • 10.3.2. Physician's Office Lab
    • 10.3.3. Urgent Care & Retail Clinics
    • 10.3.4. Home & Self-Testing
    • 10.3.5. Nursing Homes
    • 10.3.6. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Thermo Fisher Scientific Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Quest Diagnostics Incorporated
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. BD
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. bioMerieux SA
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Cardinal Health, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Cepheid
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Mesa Biotech
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Trinity Biotech
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Quidel Corporation
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bio-Rad Laboratories, Inc.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. Abbott
      • 11.2.12.1. Overview
      • 11.2.12.2. Products
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)
    • 11.2.13. Other Prominent Players

List of Tables

  • Table 01: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
  • Table 02: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 03: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 04: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 05: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
  • Table 06: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 07: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 08: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
  • Table 10: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034

8able 11: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034

  • Table 12: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 13: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
  • Table 14: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 15: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 16: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 17: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
  • Table 18: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 19: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 20: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 21: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034
  • Table 22: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 23: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 24: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034

List of Figures

  • Figure 01: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), by Region, 2025 & 2034
  • Figure 02: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025 & 2034
  • Figure 03: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Lateral Flow Immunoassay (LFIA), 2021-2034
  • Figure 04: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Agglutination Tests, 2021-2034
  • Figure 05: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Flow-through Tests / Immunoconcentration Assays, 2021-2034
  • Figure 06: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Molecular Diagnostics, 2021-2034
  • Figure 07 Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others, 2021-2034
  • Figure 08: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025 & 2034
  • Figure 09: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Human Immunodeficiency Virus (HIV) 2021-2034
  • Figure 10: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hepatitis B Virus (HBV) 2021-2034
  • Figure 11: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Pneumonia / Streptococcus Associated Infections 2021-2034
  • Figure 12: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Respiratory Syncytial Virus (RSV) 2021-2034
  • Figure 13: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Influenza 2021-2034
  • Figure 14: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Clostridium difficile infection (CDI) 2021-2034
  • Figure 15: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hepatitis C Virus (HCV) 2021-2034
  • Figure 16: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Methicillin-Resistant Staphylococcus Aureus (MRSA) 2021-2034
  • Figure 17: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Tuberculosis (TB) 2021-2034
  • Figure 18: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By COVID-19 2021-2034
  • Figure 19: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others 2021-2034
  • Figure 20: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025 & 2034
  • Figure 21: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hospital Bedside, 2021-2034
  • Figure 22: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Physician's Office Lab2021-2034
  • Figure 23: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Urgent Care & Retail Clinics 2021-2034
  • Figure 24: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Home & Self Testing 2021-2034
  • Figure 25: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Nursing Homes, 2021-2034
  • Figure 26: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others 2021-2034
  • Figure 27: Global Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Region, 2025 & 2034
  • Figure 28: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
  • Figure 29: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
  • Figure 30: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 31: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
  • Figure 32: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
  • Figure 33: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
  • Figure 34: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 35: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country, 2025
  • Figure 36: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
  • Figure 37: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
  • Figure 38: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 39: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
  • Figure 40: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
  • Figure 41: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
  • Figure 42: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
  • Figure 43: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
  • Figure 44: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
  • Figure 45: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
  • Figure 46: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 47: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
  • Figure 48: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
  • Figure 49: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
  • Figure 50: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
  • Figure 51: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
  • Figure 52: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
  • Figure 53: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
  • Figure 54: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 55: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
  • Figure 56: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
  • Figure 57: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
  • Figure 58: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
  • Figure 59: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
  • Figure 60: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034
  • Figure 61: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025
  • Figure 62: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 63: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025
  • Figure 64: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034
  • Figure 65: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025
  • Figure 66: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025
  • Figure 68: Global Infectious Disease Point-of-care (POC) Diagnostics Market Share, By Company, 2025